Ralph J. Hauke

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 627 citations · Full text

First-line Therapy, Urology, Chemotherapy Versus Chemotherapy +7

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 262 citations · Full text

Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance)

Matthew R. Smith, Susan Halabi, Charles J. Ryan et al. · Journal of Clinical Oncology · 2014 · 246 citations · Full text

Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement

Matthew I. Milowsky, R. Bryan Rumble, Christopher M. Booth et al. · Journal of Clinical Oncology · 2016 · 233 citations

ERK inhibitor PD98059 enhances docetaxel‐induced apoptosis of androgen‐independent human prostate cancer cells

Stanislav Zelivianski, Matthew Spellman, Mark Kellerman et al. · International Journal of Cancer · 2003 · 137 citations · Full text